Trial Profile
Adalimumab in Juvenile Idiopathic Arthritis for the treatment of uveitis (ADJUVITE study)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Juvenile rheumatoid arthritis; Uveitis
- Focus Therapeutic Use
- Acronyms ADJUVITE
- 23 Dec 2017 Results published in the Annals of the Rheumatic Diseases
- 05 Oct 2017 New trial record